Non-severe PVI | Severe PVI group 2 | p | |
---|---|---|---|
n=32 | n=22 | ||
Age (year)/female (%) | 44±15/ 88% | 48±12/ 87% | NS |
Duration of Raynaud's/nonRaynaud's (year) | 9±9/5±5 | 12±10/9±9 | NS |
Diffuse Cutaneous involvement | 5 (16%) | 10 (45%) | P=0,039 |
Anti-Scl70 (+) | 7 (22%) | 11 (50%) | P=0,024 |
Interstitial lung disease | 7 (22%) | 14 (64%) | P=0,001 |
Flexion contractures | 3 (9%) | 10 (45%) | P=0,008 |
Echo PAP>40 mmHg | 2 (6%) | 4 (18%) | NS |
High acute phase response | 12 (38%) | 18 (82%) | P=0,002 |
FVC ≤80%/ | 3 (9%) | 12 (55%) | P<0,001 |
DLCO ≤80% | 10 (31%) | 14 (64%) | P=0,011 |
Immunosuppressives- CYC (pulse) | 5 (16%) | 9 (41%) | P=0,018 |
– Azathioprin | 8 (25%) | 10 (46%) | P=0,030 |
– Mycphenolate mofetil | 2 (6%) | 10 (46%) | P<0,001 |
– Rituksimab | 1 (3%) | 6 (27%) | P=0,027 |
– Steroids (PRD<10 mg/d) | 11 (34%) | 17 (77%) | P=0,001 |
NS = not significant.